AR127806A1 - Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 - Google Patents
Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15Info
- Publication number
- AR127806A1 AR127806A1 ARP220103274A ARP220103274A AR127806A1 AR 127806 A1 AR127806 A1 AR 127806A1 AR P220103274 A ARP220103274 A AR P220103274A AR P220103274 A ARP220103274 A AR P220103274A AR 127806 A1 AR127806 A1 AR 127806A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion proteins
- antibodies
- antigen
- binding
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan anticuerpos recombinantes, fragmentos de unión a antígeno de los mismos y proteínas de fusión de los mismos útiles para unirse a B7-H4 e inhibirlo. También se proporcionan moléculas de ácido nucleico que codifican los anticuerpos, los fragmentos de unión a antígeno de los mismos y las proteínas de fusión de los mismos descritos en la presente memoria y las composiciones terapéuticas de los mismos. Se describen otros métodos de uso de los anticuerpos descritos, sus fragmentos de unión a antígeno y sus proteínas de fusión para el tratamiento de enfermedades. Reivindicación 66: Un vector que comprende el ácido nucleico de la reivindicación 66. Reivindicación 70: Una célula T que expresa una proteína de unión a anti-B7-H4 que comprende las cadenas variables pesada y ligera del anticuerpo anti-B7-H4, o un fragmento de unión a antígeno del mismo, de cualquiera de las reivindicaciones 1 - 33. Reivindicación 94: Un método para detectar B7-H4 en una muestra, el método comprende poner en contacto la muestra con el anticuerpo anti-B7-H4, o fragmento de unión a antígeno del mismo, de cualquiera de las reivindicaciones 1 - 33 o la proteína de fusión de cualquiera de las reivindicaciones 34 - 65.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284937P | 2021-12-01 | 2021-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127806A1 true AR127806A1 (es) | 2024-02-28 |
Family
ID=84519919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103274A AR127806A1 (es) | 2021-12-01 | 2022-11-29 | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312724A1 (es) |
| EP (1) | EP4441093A1 (es) |
| JP (1) | JP2024543942A (es) |
| KR (1) | KR20240112342A (es) |
| CN (1) | CN118339184A (es) |
| AR (1) | AR127806A1 (es) |
| AU (1) | AU2022402985A1 (es) |
| CA (1) | CA3238965A1 (es) |
| CO (1) | CO2024008181A2 (es) |
| IL (1) | IL313159A (es) |
| MX (1) | MX2024006573A (es) |
| TW (1) | TW202346320A (es) |
| WO (1) | WO2023102367A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ES2861435T3 (es) * | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
| CN104955475A (zh) * | 2012-12-19 | 2015-09-30 | 艾普利穆恩公司 | 抗人b7-h4抗体及其用途 |
| HUE057917T2 (hu) * | 2014-01-15 | 2022-06-28 | Kadmon Corp Llc | Immunmodulátor szerek |
| US10059768B2 (en) * | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| CN119552248A (zh) | 2017-08-25 | 2025-03-04 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| WO2019126227A1 (en) * | 2017-12-18 | 2019-06-27 | Distributed Bio, Inc. | Radically diverse human antibody library |
| MX2020008181A (es) * | 2018-02-11 | 2020-09-18 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. |
| RU2020128440A (ru) * | 2018-02-28 | 2022-03-28 | Пфайзер Инк. | Варианты il-15 и их применения |
-
2022
- 2022-11-29 TW TW111145737A patent/TW202346320A/zh unknown
- 2022-11-29 AU AU2022402985A patent/AU2022402985A1/en active Pending
- 2022-11-29 US US18/059,548 patent/US20230312724A1/en active Pending
- 2022-11-29 EP EP22823298.9A patent/EP4441093A1/en active Pending
- 2022-11-29 CA CA3238965A patent/CA3238965A1/en active Pending
- 2022-11-29 JP JP2024532180A patent/JP2024543942A/ja active Pending
- 2022-11-29 KR KR1020247021496A patent/KR20240112342A/ko active Pending
- 2022-11-29 IL IL313159A patent/IL313159A/en unknown
- 2022-11-29 AR ARP220103274A patent/AR127806A1/es unknown
- 2022-11-29 WO PCT/US2022/080542 patent/WO2023102367A1/en not_active Ceased
- 2022-11-29 MX MX2024006573A patent/MX2024006573A/es unknown
- 2022-11-29 CN CN202280079188.6A patent/CN118339184A/zh active Pending
-
2024
- 2024-06-24 CO CONC2024/0008181A patent/CO2024008181A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313159A (en) | 2024-07-01 |
| MX2024006573A (es) | 2024-06-11 |
| CO2024008181A2 (es) | 2024-06-27 |
| EP4441093A1 (en) | 2024-10-09 |
| WO2023102367A1 (en) | 2023-06-08 |
| AU2022402985A1 (en) | 2024-07-11 |
| JP2024543942A (ja) | 2024-11-26 |
| KR20240112342A (ko) | 2024-07-18 |
| CN118339184A (zh) | 2024-07-12 |
| TW202346320A (zh) | 2023-12-01 |
| US20230312724A1 (en) | 2023-10-05 |
| CA3238965A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024540A2 (pt) | Métodos para selecionar uma célula ou um vírus, determinar a sequência de um ácido nucleico, produzir uma célula que expressa um ácido nucleico e tratar um sujeito, célula imune selecionada e método para selecionar uma célula imune | |
| CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| CL2018001827A1 (es) | Proteína de unión de tipo anticuerpo con región variable dual que comprende cuatro cadenas polipeptídicas que forman cuatro sitios de unión a antígeno; molécula de ácido nucleico que la codifica; vector de expresión; célula; método de elaboración; y composición farmacéutica que la comprende (divisional solicitud 201302763) | |
| BR112018070823A2 (pt) | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. | |
| MX2021001074A (es) | Ratones de cadena ligera universal humanizados. | |
| MX2015008045A (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano. | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| BRPI0507433C1 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
| PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
| DK2053408T3 (da) | Fremgangsmåde til strukturel karakterisering af et rekombinant polyklonalt protein eller en polyklonal cellelinje | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| UY38807A (es) | Proteínas de unión a antígeno anti-il13 | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| JOP20200215A1 (ar) | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها | |
| AR102095A1 (es) | Método para medir la reactividad del fviii | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
| EA202091713A1 (ru) | Биологический синтез аминокислотных цепей для получения пептидов и белков | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| PE20181498A1 (es) | Anticuerpos monoclonales especificos para el antigeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por adv | |
| AR127806A1 (es) | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 |